Pearlie K. Burnette, PharmD, PhD

Where You Are:
Pearlie K. Burnette, PharmD, PhD

Senior Member

"Increased awareness of the MLS burden has advanced the study of the molecular basis of this complex disease to develop new treatments."

Office  (813) 745-6177

Education And Training
  • PhD, University of South Florida, 1994 - Medical Sciences
  • PharmD, University of Florida, 1989 - Pharmacy


Chronic lymphocytosis of large granular lymphocytes (LGL) associated with neutropenia and/or anemia was first described in 1985 to be the result of clonal cytogenetic abnormalities. These LGL proliferations are now recognized as being clonally derived from either CD3- or CD3+ LGL, and the resulting diseases are designated natural killer (NK)-LGL leukemia and T-LGL leukemia, respectively. Peripheral elimination of normal activated NK- and T-LGL cells occurs through apoptosis by a Fas (CD95)-mediated pathway. Therefore, the central hypothesis of Dr. Epling-Burnette and her colleagues is that the LGL cells accumulate as a result of dysregulated apoptosis and that these lymphocytes induce autoimmune destruction of myeloid and/or erythroid populations.

Research in our laboratory has focused on the inhibitors of apoptosis that might directly mediate survival of these cells and contribute to their resistance to Fas signaling. We have identified several survival pathways that are chronically active in patients with these diseases and contribute to accumulation of LGL cells. Signal transducers and activators of transcription (STAT) signaling has been found to regulate antiapoptotic survival in some tumors. STATs are transcription factors initially discovered as key signaling components that moderate responses to cytokine stimulation. We have data implicating STAT3 in the survival of NK- and T-LGLs. Mcl-1 is transcriptionally regulated by STAT3 and prevents apoptosis at the level downstream of Fas receptor signaling.

The mitogen-activated protein kinase (MAPK/ERK) pathway is another cascade that is important in LGL survival. We have found that MAPK/ERK was constitutively activated in 13 of 13 patients with NK-LGL leukemia and six of seven patients with T-LGL leukemia. The MAPK pathway coupled long-term survival of these LGL cells to constitutively activated Ras. These findings suggest that strategies to inhibit STAT or Ras/ERK/MAPK signaling pathways may be useful for the treatment of LGL leukemias.

I am also is interested in the mechanism of bone marrow failure in patients with LGL leukemia. A large number of NK receptors (killer cell immunoglobulin-like receptors, or KIRs) are expressed on NK cells and some T cells that recognize self-HLA alleles, thereby limiting the lysis of autologous cells. Ligands of the inhibitory KIRs are classic HLA Class I molecules, and engagement of these receptors inhibits the lytic activity of NK and T cells. Activating NK receptors are important in the recognition of tumor cells and virus-infected cells and mediate target cell lysis. We have found that the repertoire of NK receptors expressed on NK-LGL cells is skewed. Interestingly, patients with NK-LGL leukemia express a large number of activating KIRs (by genotype analysis) and lower levels of inhibitory KIR mRNA and protein than normal NK cells. Consistent with a high level of activating NK receptors, the NK-LGL cells have a potent cytolytic function. These results demonstrate that patients with NK-LGL leukemia have an increased activating-to-inhibitory KIR ratio. The major hypothesis guiding this research is that this altered ratio induces inappropriate lysis or cytokine production that has an impact on bone marrow production of erythroid and/or myeloid cells.

  • Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution. Acta Haematol. 2014 Nov;133(2):249-256. Pubmedid: 25413011.
  • Komrokji RS, Mailloux AW, Chen DT, Sekeres MA, Paquette R, Fulp WJ, Sugimori C, Paleveda-Pena J, Maciejewski JP, List AF, Epling-Burnette PK. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica. 2014 Jul;99(7):1176-1183. Pubmedid: 24488560.
  • Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, Sekeres MA, Painter JS, Zhang L, Lancet J, Maciejewski JP, Epling-Burnette PK, Sotomayor E, Komrokji RS, List AF. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood. 2014 Jun;123(23):3675-3677. Pubmedid: 24904105. Pmcid: PMC4047502.
  • Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, Epling-Burnette P, Van Bijnen S, Dolstra H, Cannon J, Youn JI, Donatelli SS, Qin D, De Witte T, Tao J, Wang H, Cheng P, Gabrilovich DI, List A, Wei S. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. 2013 Nov;123(11):4595-4611. Pubmedid: 24216507. Pmcid: PMC3809779.
  • Mailloux AW, Zhang L, Moscinski L, Bennett JM, Yang L, Yoder SJ, Bloom G, Wei C, Wei S, Sokol L, Loughran TP, Epling-Burnette PK. Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia. J Immunol. 2013 Oct;191(7):3578-3593. Pubmedid: 24014875.
  • Anic GM, Sondak VK, Messina JL, Fenske NA, Zager JS, Cherpelis BS, Lee JH, Fulp WJ, Epling-Burnette PK, Park JY, Rollison DE. Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol. 2013 Aug;37(4):434-439. Pubmedid: 23523330. Pmcid: PMC3679277.
  • Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Aug;121(25):5068-5077. Pubmedid: 23632888.
  • Duong VH, Lancet JE, Alrawi E, Al-Ali NH, Perkins J, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leuk Res. 2013 May;37(5):510-515. Pubmedid: 23332452.
  • Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia. 2013 Apr;27(4):897-906. Pubmedid: 23072779.
  • Mailloux AW, Epling-Burnette PK. Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes. Oncoimmunology. 2013 Feb;2(2):e22654. Pubmedid: 23524348. Pmcid: PMC3601152.
  • Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013 Feb;32(9):1110-1120. Pubmedid: 22525275. Pmcid: PMC3751397.
  • Epling-Burnette PK, McDaniel J, Wei S, List AF. Emerging immunosuppressive drugs in myelodysplastic syndromes. Expert Opin Emerg Drugs. 2012 Dec;17(4):519-541. Pubmedid: 23163589.
  • Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov;87(11):1006-1009. Pubmedid: 23090887.
  • Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP, List AF, Epling-Burnette PK. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol. 2012 Sep;189(6):3198-3208. Pubmedid: 22875800. Pmcid: PMC3436939.
  • Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW, Zanesi N, Epling-Burnette PK, Sotomayor EM, Croce CM, Del Valle JR, Hu CC. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood. 2012 Aug;120(5):1027-1038. Pubmedid: 22692508. Pmcid: PMC3680046.
  • McDaniel JM, Zou JX, Fulp W, Chen DT, List AF, Epling-Burnette PK. Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia. 2012 Jun;26(6):1425-1429. Pubmedid: 22193963. Pmcid: PMC3321111.
  • Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, Maciejewski JP, Loughran TP. Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leuk Res. 2012 May;36(5):581-587. Pubmedid: 22386729. Pmcid: PMC3312981.
  • Bai F, Villagra AV, Zou J, Painter JS, Connolly K, Blaskovich MA, Sokol L, Sebti S, Djeu JY, Loughran TP, Wei S, Sotomayor E, Epling-Burnette P. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immunother. 2012 Apr;61(4):523-533. Pubmedid: 21983879.
  • Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar;2(3):e63. Pubmedid: 22829258. Pmcid: PMC3317526.
  • McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol. 2012;2012:513702. Pubmedid: 22888354. Pmcid: PMC3409527.
  • Zhou J, Eksioglu EA, Fortenbery NR, Chen X, Wang H, Epling-Burnette PK, Djeu JY, Wei S. Bone marrow mononuclear cells up-regulate toll-like receptor expression and produce inflammatory mediators in response to cigarette smoke extract. PLoS One. 2011 Dec;6(6):e21173. Pubmedid: 21738617. Pmcid: PMC3126797.
  • Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF. Telomere length in myelodysplastic syndromes. Leuk Lymphoma. 2011 Aug;52(8):1528-1536. Pubmedid: 21635204.
  • Zhou J, Wu J, Chen X, Fortenbery N, Eksioglu E, Kodumudi KN, Epling-Burnette PK, Dong J, Djeu JY, Wei S. Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. Int Immunopharmacol. 2011 Jul;11(7):890-898. Pubmedid: 21244860. Pmcid: PMC3109231.
  • Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011 Apr;52(4):668-679. Pubmedid: 21271862.
  • Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. 2009 Aug;106(31):12974-12979. Pubmedid: 19470455. Pmcid: PMC2722346.
  • Zou JX, Rollison DE, Boulware D, Chen DT, Sloand EM, Pfannes LV, Goronzy JJ, Bai F, Painter JS, Wei S, Cosgrove D, List AF, Epling-Burnette PK. Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia. 2009 Jul;23(7):1288-1296. Pubmedid: 19282834. Pmcid: PMC3252820.
  • Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, Sallman DA, Chen YA, Yoder JA, Djeu JY, Loughran TP, Epling-Burnette PK, Wei S. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood. 2009 Apr;113(14):3226-3234. Pubmedid: 19075187. Pmcid: PMC2665892.
  • Epling-Burnette PK, List AF. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol. 2009 Mar;16(2):70-76. Pubmedid: 19468267.
  • Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, Zou J, Painter JS, Edwards TD, Moscinski L, Yoder JA, Djeu JY, Sebti S, Loughran TP, Wei S. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 2008 Dec;112(12):4694-4698. Pubmedid: 18791165. Pmcid: PMC2597136.
  • Lai D, Loughran TP J, Maciejewski J, Sasu S, Song S, Burnette P, Paquette R. Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia. Leuk Res. 2008 May;32(5):823-827. Pubmedid: 17915315.
  • Yang J, Epling-Burnette PK, Painter JS, Zou J, Bai F, Wei S, Loughran TP. Antigen activation and impaired Fas-induced DISC formation in LGL leukemia. Blood. 2008 Feb;111(3):1610-1616. Pubmedid: 17993614.
  • Jiang K, Apostolatos AH, Ghansah T, Watson JE, Vickers T, Cooper DR, Epling-Burnette PK, Patel NA. Identification of a novel antiapoptotic human protein kinase C delta isoform, PKCdeltaVIII in NT2 cells. Biochemistry-Us. 2008 Jan;47(2):787-797. Pubmedid: 18092819.
  • Bourgault-Rouxel A, Loughran TP, Zambello R, Burnette P, SemenzatoG, Donadieu J, Amiot L, Fest T, Lamy T. Clinical spectrum of gammadelta+ T cell LGL leukemia: analysis of 20 cases. Leuk Res. 2008 Jan;32(1):45-48. Pubmedid: 17544120.
  • Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, ZouJ, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, Djeu JY, List AF. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007 Jun;109(11):4816-4824. Pubmedid: 17341666.
  • Epling-Burnette PK, Painter JS, Rollison DE, Ku E, Vendron D, Widen R, Boulware D, Zou JX, Bai F, List AF. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia. 2007 Apr;21(4):659-667. Pubmedid: 17301813.
  • Gallagher S, Peng Y, Haines K, Baksh K, Epling-Burnette P, Yang J, Murr MM. Fas/FasL play a central role in pancreatitis-induced hepatocyte apoptosis. J Gastrointest Surg. 2005 Apr;9(4):467-474. Pubmedid: 15797225.
  • Epling-Burnette PK, Bai F, Wei S, Painter JS, Olashaw N, Hamilton A, Sebti S, Djeu JY, Loughran TP. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene. 2004 Dec;23(57):9220-9229. Pubmedid: 15516985.
  • Yang J, Gallagher S, Haines K, Epling-Burnette P, Bai F, Gower WR J, Mastorides S, Norman J, Murr M. Kupffer cell-derived Fas ligand plays a role in liver injury and hepatocyte death. J Gastrointest Surg. 2004;8(2):166-174. Pubmedid: 15036192.
  • Gallagher S, Yang J, Baksh K, Haines K, Carpenter H, Epling-Burnette P, Peng Y, Norman J, Murr M. Acute pancreatitis induces FasL gene expression and apoptosis in the liver. J Surg Res. 2004;122(2):201-209. Pubmedid: 15555619.
  • Epling-Burnette P, Painter J, Bai F, Wei S, Djeu J, LoughranTP. Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood. 2004;103(9):3431-3439. Pubmedid: 14726391.
  • Mohapatra S, Chu B, Wei S, Djeu J, Epling-Burnette PK, Loughran T, Jove R, Pledger WJ. Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res. 2003 Dec;63(23):8523-8530. Pubmedid: 14679020.
  • Zhong B, Jiang K, Gilvary DL, Epling-Burnette PK, Ritchey C, Liu J, Jackson RJ, Hong-Geller E, Wei S. Human neutrophils utilize a Rac/Cdc42-dependent MAPK pathway to direct intracellular granule mobilization toward ingested microbial pathogens. Blood. 2003 Jun;101(8):3240-3248. Pubmedid: 12511425.
  • Yang J, Fier A, Carter Y, Liu G, Epling-Burnette P, Bai F, Loughran TP J, Mastorides S, Norman J, Murr M. Liver injury during acute pancreatitis: the role of pancreatitis-associated ascitic fluid (PAAF), p38-MAPK, and caspase-3 in inducing hepatocyte apoptosis. J Gastrointest Surg. 2003;7(2):200-208. Pubmedid: 12600444.
  • Epling-Burnette P, Loughran TP J. Survival signals in leukemic large granular lymphocytes. Semin Hematol. 2003;40:213-220. Pubmedid: 12876670.
  • Kothapalli R, Bailey R, Kusmartseva I, Mane S, Epling-Burnette P, Loughran TP. Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int J Oncol. 2003;22(1):33-39. Pubmedid: 12469182.
  • Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002 Dec;21(57):8804-8816. Pubmedid: 12483533.
  • Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2002 Oct;62(20):5761-5769. Pubmedid: 12384536.
  • Murr M, Yang J, Fier A, Foulis P, Loughran T, Epling-Burnette P, Norman J. Pancreatitis-associated ascitic fluid induces hepatocyte death independent of local cytokines. J Surg Res. 2002;106(2):308-313. Pubmedid: 12175984.
  • Liu J, Wei S, Lamy T, Yongxiang L, Epling-Burnette P, Djeu J, Loughran T. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood. 2002;100(4):1449-1453. Pubmedid: 12149230.
  • Epling-Burnette PK, Zhong B, Bai F, Jiang K, Bailey RD, Garcia R, Jove R, Djeu JY, Loughran TP, Wei S. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol. 2001 Jun;166(12):7486-7495. Pubmedid: 11390502.
  • Epling-Burnette P, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TP. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107(3):351-362. Pubmedid: 11160159.
  • Wei S, Liu JH, Epling-Burnette PK, Jiang K, Zhong B, Elkabani ME, Pearson EW, Djeu JY. IL-2 induces the association of IL-2Rbeta, lyn, and MAP kinase ERK-1 in human neutrophils. Immunobiology. 2000 Nov;202(4):363-382. Pubmedid: 11131153.
  • Liu J, Wei S, Lamy T, Loughran, Jr. T, Epling-Burnette P, Starkebaum G, Djeu J. Chronic neutropenia mediated by fas ligand. Blood. 2000;95(10):3219-3222. Pubmedid: 10807792.
  • Liu J, Wei S, Burnette P, Gamero A, Ussery D, Djeu J. Functional association of TGF-beta receptor II with cyclin B. Oncogene. 1999;18(1):269-275. Pubmedid: 9926943.
  • Pericle F, Burnette P, Podack E, Wei S, Djeu J. CD4-CD40L interactions provide "third-party" costimulation for T cell response against B7-1 transfected human breast tumor cells. J Leukoc Biol. 1997;61:201-208. Pubmedid: 9021926.
  • Spranzi E, Djeu JY, Hoffman SL, Epling-Burnette PK, Blanchard DK. Lysis of human monocytic leukemia cells by extracellular adenosine triphosphate: mechanism and characterization of the adenosine triphosphate receptor. Blood. 1993 Sep;82(5):1578-1585. Pubmedid: 8364207.
  • Burnette P, Wei S, Blanchard D, Spranzi E, Djeu J. Co-induction of GM-CSF release and LAK susceptibility in monocytes by IL-2 via Il-2R(beta). Blood. 1993;81:3130-3130.
  • Burnette PK, Perkins J. Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting. Pharmacotherapy. 1992;12(2):120-131. Pubmedid: 1533280.
  • Mattingly PM, Burnette PK, Weston MW, Manny RP. Pancytopenia secondary to short-term, high-dose intravenous infusion of amrinone. DICP. 1990 Dec;24(12):1172-1174. Pubmedid: 2089824.
  • Burnette PK, Ameer B, Hoang V, Phifer W. Rifampin-associated thrombocytopenia secondary to poor compliance. DICP. 1989 May;23(5):382-384. Pubmedid: 2728526.
  • Epling-Burnette PK, Garcia R, Catlet-Falcone R, Liu J, Gamero M, Yu L, Jove R, Djeu J, Wei S. Carboxy-terminal truncated STAT5 is induced by interleukin-2 and GM-CSF in human neutrophils. Cell Immunol. 217(1-2):1-11. Pubmedid: 12425996.
  • Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP Jr, List AF, Epling-Burnette PK. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol. 2012 Sept;189(6):198-208. Pmcid: PMC3436939.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions